These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 38845820)

  • 1. Metabolic dysfunction-associated steatotic liver disease heterogeneity: Need of subtyping.
    Habib S
    World J Gastrointest Pathophysiol; 2024 May; 15(2):92791. PubMed ID: 38845820
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Association of Metabolic Dysfunction-Associated Steatotic Liver Disease/Non-alcoholic Fatty Liver Disease With Type 2 Diabetes Mellitus: A Case-Control Study in a Tertiary Care Hospital in Pakistan.
    Zahoor F; Saeed NU; Javed S; Sadiq HZ; Mand Khan F; Haider M; Shafqat MN; Maqbool A; Chaudhry A
    Cureus; 2023 Oct; 15(10):e47240. PubMed ID: 38021965
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Machine learning identification of risk factors for heart failure in patients with diabetes mellitus with metabolic dysfunction associated steatotic liver disease (MASLD): the Silesia Diabetes-Heart Project.
    Nabrdalik K; Kwiendacz H; Irlik K; Hendel M; Drożdż K; Wijata AM; Nalepa J; Janota O; Wójcik W; Gumprecht J; Lip GYH
    Cardiovasc Diabetol; 2023 Nov; 22(1):318. PubMed ID: 37985994
    [TBL] [Abstract][Full Text] [Related]  

  • 4. From metabolic dysfunction-associated fatty liver disease to metabolic dysfunction-associated steatotic liver disease: Controversy and consensus.
    Chen L
    World J Hepatol; 2023 Dec; 15(12):1253-1257. PubMed ID: 38223415
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mitochondrial Quality Control: Its Role in Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD).
    Shin S; Kim J; Lee JY; Kim J; Oh CM
    J Obes Metab Syndr; 2023 Dec; 32(4):289-302. PubMed ID: 38049180
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Insulin resistance and central obesity determine hepatic steatosis and explain cardiovascular risk in steatotic liver disease.
    Semmler G; Balcar L; Wernly S; Völkerer A; Semmler L; Hauptmann L; Wernly B; Aigner E; Niederseer D; Datz C
    Front Endocrinol (Lausanne); 2023; 14():1244405. PubMed ID: 37842290
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Metabolic-Dysfunction-Associated Steatotic Liver Disease-Its Pathophysiology, Association with Atherosclerosis and Cardiovascular Disease, and Treatments.
    Yanai H; Adachi H; Hakoshima M; Iida S; Katsuyama H
    Int J Mol Sci; 2023 Oct; 24(20):. PubMed ID: 37895151
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pathology and Pathogenesis of Metabolic Dysfunction-Associated Steatotic Liver Disease-Associated Hepatic Tumors.
    Takahashi Y; Dungubat E; Kusano H; Fukusato T
    Biomedicines; 2023 Oct; 11(10):. PubMed ID: 37893134
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Vitamin D and Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD): Novel Mechanistic Insights.
    Aggeletopoulou I; Tsounis EP; Triantos C
    Int J Mol Sci; 2024 Apr; 25(9):. PubMed ID: 38732118
    [TBL] [Abstract][Full Text] [Related]  

  • 10. 2024 UPDATE: the Brazilian Diabetes Society position on the management of metabolic dysfunction-associated steatotic liver disease (MASLD) in people with prediabetes or type 2 diabetes.
    Godoy-Matos AF; Valério CM; Silva Júnior WS; de Araujo-Neto JM; Bertoluci MC
    Diabetol Metab Syndr; 2024 Jan; 16(1):23. PubMed ID: 38238868
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacological therapy of metabolic dysfunction-associated steatotic liver disease-driven hepatocellular carcinoma.
    Wang Y; Fleishman JS; Li T; Li Y; Ren Z; Chen J; Ding M
    Front Pharmacol; 2023; 14():1336216. PubMed ID: 38313077
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD): A State-of-the-Art Review.
    Chan WK; Chuah KH; Rajaram RB; Lim LL; Ratnasingam J; Vethakkan SR
    J Obes Metab Syndr; 2023 Sep; 32(3):197-213. PubMed ID: 37700494
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Type 2 diabetes mellitus and cardiometabolic outcomes in metabolic dysfunction-associated steatotic liver disease population.
    Chew NWS; Pan XH; Chong B; Chandramouli C; Muthiah M; Lam CSP
    Diabetes Res Clin Pract; 2024 May; 211():111652. PubMed ID: 38574897
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of Wild-Type and High-risk PNPLA3 variants in a Human Biomimetic Liver Microphysiology System for Metabolic Dysfunction-associated Steatotic Liver Disease Precision Therapy.
    Xia M; Varmazyad M; Palacin IP; Gavlock DC; Debiasio R; LaRocca G; Reese C; Florentino R; Faccioli LAP; Brown JA; Vernetti LA; Schurdak ME; Stern AM; Gough A; Behari J; Soto-Gutierrez A; Taylor DL; Miedel M
    bioRxiv; 2024 May; ():. PubMed ID: 38712213
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Non-invasive Scores and Serum Biomarkers for Fatty Liver in the Era of Metabolic Dysfunction-associated Steatotic Liver Disease (MASLD): A Comprehensive Review From NAFLD to MAFLD and MASLD.
    Abdelhameed F; Kite C; Lagojda L; Dallaway A; Chatha KK; Chaggar SS; Dalamaga M; Kassi E; Kyrou I; Randeva HS
    Curr Obes Rep; 2024 Sep; 13(3):510-531. PubMed ID: 38809396
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Longitudinal Outcomes Associated With Metabolic Dysfunction-Associated Steatotic Liver Disease: A Meta-analysis of 129 Studies.
    Chan KE; Ong EYH; Chung CH; Ong CEY; Koh B; Tan DJH; Lim WH; Yong JN; Xiao J; Wong ZY; Syn N; Kaewdech A; Teng M; Wang JW; Chew N; Young DY; Know A; Siddiqui MS; Huang DQ; Tamaki N; Wong VW; Mantzoros CS; Sanyal A; Noureddin M; Ng CH; Muthiah M
    Clin Gastroenterol Hepatol; 2024 Mar; 22(3):488-498.e14. PubMed ID: 37775028
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Adverse pregnancy outcomes as a risk factor for new-onset metabolic dysfunction-associated steatotic liver disease in postpartum women: A nationwide study.
    Jung YM; Lee SM; Wi W; Oh MJ; Park JS; Cho GJ; Kim W
    JHEP Rep; 2024 Apr; 6(4):101033. PubMed ID: 38524668
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Trends in Oxidative Balance Score and Prevalence of Metabolic Dysfunction-Associated Steatotic Liver Disease in the United States: National Health and Nutrition Examination Survey 2001 to 2018.
    Tan Z; Wu Y; Meng Y; Liu C; Deng B; Zhen J; Dong W
    Nutrients; 2023 Nov; 15(23):. PubMed ID: 38068789
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Epidemiology, screening, and co-management of type 2 diabetes mellitus and metabolic dysfunction-associated steatotic liver disease.
    Qi X; Li J; Caussy C; Teng GJ; Loomba R
    Hepatology; 2024 May; ():. PubMed ID: 38722246
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phenotypes of Metabolic Dysfunction-Associated Steatotic Liver Disease-Associated Hepatocellular Carcinoma.
    Rivera-Esteban J; Muñoz-Martínez S; Higuera M; Sena E; Bermúdez-Ramos M; Bañares J; Martínez-Gomez M; Cusidó MS; Jiménez-Masip A; Francque SM; Tacke F; Minguez B; Pericàs JM
    Clin Gastroenterol Hepatol; 2024 Sep; 22(9):1774-1789.e8. PubMed ID: 38604295
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.